Evidence map›Paper›PMID 42179066›Full record

ArticleBritish journal of haematology2026

Utility of combined CD39/CD73/CD38 expression for the detection of malignant T cells in Sézary syndrome.

Sara Marchisio, Yuliya Yakymiv, Liyun Lin, Erika Ortolan, Verdiana Pullano, Renata Ponti, Fenna J de Bie, Alita J van der Sluijs-Gelling, Willem H Zoutman, Valentina Pala and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sara MarchisioLaboratory of Immunogenetics, Department of Medical Sciences, University of Turin, Turin, Italy.ORCID https://orcid.org/0000-0001-7005-837X
Yuliya YakymivLaboratory of Immunogenetics, Department of Medical Sciences, University of Turin, Turin, Italy.ORCID https://orcid.org/0000-0002-9598-3462
Liyun LinLaboratory of Immunogenetics, Department of Medical Sciences, University of Turin, Turin, Italy.ORCID https://orcid.org/0009-0005-6870-0251
Erika OrtolanLaboratory of Immunogenetics, Department of Medical Sciences, University of Turin, Turin, Italy.ORCID https://orcid.org/0000-0003-2287-9020
Verdiana PullanoDepartment of Neuroscience 'Rita Levi Montalcini', University of Turin, Turin, Italy.ORCID https://orcid.org/0000-0002-0409-9832
Renata PontiDepartment of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
Fenna J de BieDepartment of Dermatology, Leiden University Medical Center, Leiden, the Netherlands.ORCID https://orcid.org/0000-0003-3817-8616
Alita J van der Sluijs-GellingDepartment of Dermatology, Leiden University Medical Center, Leiden, the Netherlands.
Willem H ZoutmanDepartment of Dermatology, Leiden University Medical Center, Leiden, the Netherlands.ORCID https://orcid.org/0000-0003-0085-3647
Valentina PalaDepartment of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.ORCID https://orcid.org/0000-0002-3504-2417
Ferenc A ScheerenDepartment of Dermatology, Leiden University Medical Center, Leiden, the Netherlands.ORCID https://orcid.org/0000-0002-8304-9023
Maarten H VermeerDepartment of Dermatology, Leiden University Medical Center, Leiden, the Netherlands.ORCID https://orcid.org/0000-0002-5872-4613
Ada FunaroLaboratory of Immunogenetics, Department of Medical Sciences, University of Turin, Turin, Italy.ORCID https://orcid.org/0000-0001-6341-1817
Pietro QuaglinoDepartment of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.ORCID https://orcid.org/0000-0003-4185-9586
Gabriele RoccuzzoDepartment of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.ORCID https://orcid.org/0000-0001-7126-5506

Funding

IMMUNO-CANCER-PRIN-2021KWF Dutch Cancer SocietyResearch Projects of National Relevant Interest 20209KY3Y7
6 · The paper itself

Abstract

Sézary syndrome (SS) is an aggressive cutaneous T-cell lymphoma, characterized by erythroderma, lymphadenopathy and circulating malignant CD4

Indexed as

5'-NucleotidaseADP-ribosyl Cyclase 1Antigens, CDApyraseBiomarkers, TumorSezary SyndromeSkin NeoplasmsAgedAged, 80 and overCD4-Positive T-LymphocytesFemaleFlow CytometryGPI-Linked ProteinsHumansMaleMembrane Glycoproteins5'-NucleotidaseADP-ribosyl Cyclase 1Antigens, CDApyraseBiomarkers, TumorCD38 protein, humanCD39 antigenENTPD1 protein, humanGPI-Linked ProteinsMembrane GlycoproteinsNT5E protein, humanCD38CD39CD73flow cytometrySézary syndrometumour markers

Identifiers

PMID42179066
PMCPMC13340541

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.